Literature DB >> 7686931

Altered protein tyrosine phosphorylation in anergic Th1 cells.

E A Cho1, M P Riley, A L Sillman, H Quill.   

Abstract

Clonal anergy as a mechanism for tolerance in T lymphocytes can be studied using an in vitro culture system, in which cloned CD4+ Th1-type murine T cells are rendered anergic for IL-2 transcription. The long-lasting molecular changes in anergic cells that prevent the response to Ag restimulation are not yet known. To determine whether the TCR might be uncoupled from normal intracellular signaling pathways, we investigated the response of anergic T cells to Ag, to anti-CD3 antibodies, or to anti-CD4 antibody restimulation in terms of early protein tyrosine phosphorylation events. Tyrosine phosphorylation of the CD3 zeta chain was apparently normal. In contrast, defects in the induction of tyrosine phosphorylation of three major T cell protein substrates were demonstrated. Altered phosphorylation correlated with functional nonresponsiveness for proliferation and reversal of anergy by growth in exogenous IL-2 resulted in reversal of the phosphorylation defects as well as in recovery of Ag responsiveness. These results suggest that specific defects in tyrosine phosphorylation pathways required for the induction of IL-2 synthesis may help to explain nonresponsiveness to Ag in tolerant T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686931

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

Review 1.  T-cell anergy: from phenotype to genotype and back.

Authors:  Christine M Seroogy; C Garrison Fathman
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

Review 3.  Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires.

Authors:  C C Goodnow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 4.  New immunosuppressive drugs: mechanistic insights and potential therapeutic advances.

Authors:  A W Thomson; T E Starzl
Journal:  Immunol Rev       Date:  1993-12       Impact factor: 12.988

5.  Cord blood CD4+ CD45RA+ T cells achieve a lower magnitude of activation when compared with their adult counterparts.

Authors:  J Hassan; D J Reen
Journal:  Immunology       Date:  1997-03       Impact factor: 7.397

6.  Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.

Authors:  Y D Korin; J A Zack
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

7.  Staphylococcal enterotoxins modulate interleukin 2 receptor expression and ligand-induced tyrosine phosphorylation of the Janus protein-tyrosine kinase 3 (Jak3) and signal transducers and activators of transcription (Stat proteins).

Authors:  M Nielsen; A Svejgaard; C Röpke; M Nordahl; N Odum
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

8.  In vitro T cell unresponsiveness following low-dose injection of anti-CD3 MoAb.

Authors:  A Ben-Amor; M C Leite-De-Moraes; F Lepault; E Schneider; F Machavoine; A Arnould; L Chatenoud; M DY
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

9.  Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists.

Authors:  J Madrenas; R H Schwartz; R N Germain
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

Review 10.  Anergy and suppression as coexistent mechanisms for the maintenance of peripheral T cell tolerance.

Authors:  Patrick J Brennan; Sandra J Saouaf; Mark I Greene; Yuan Shen
Journal:  Immunol Res       Date:  2003       Impact factor: 4.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.